# Palonosetron

## OKmilon inj 0.25mg/5mL

| TAH Drug Code      | [IOKM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOKM)                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Adults: Prevention of chemotherapy-induced nausea and vomiting. -Moderately nauseogenic cancer chemotherapy - Prevention of acute and delayed nausea and vomiting during initial and recurrent courses. -Highly nauseogenic cancer chemotherapy - Prevention of acute nausea and vomiting during initial and recurrent courses. Children and adolescents (1 month to 17 years) -Prevention of acute nausea and vomiting during highly nauseogenic cancer chemotherapy. -Prevention of moderately nauseogenic cancer chemotherapy. |
| Dosing             | Chemotherapy-induced nausea and vomiting, associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg.                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity to palonosetron or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common Cardiovascular: Bradyarrhythmia (1% to 4% ); Gastrointestinal: Constipation (up to 5% ); Neurologic: Headache (up to 9% ) Serious Cardiovascular: Prolonged QT interval; Immunologic: Anaphylaxis, Hypersensitivity reaction; Neurologic: Seizure; Other: Serotonin syndrome                                                                                                                                                                                                                                               |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/palonosetron-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

